Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. more
Time Frame | AVTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.91% | 1.76% | -2.5% |
1-Month Return | -25.57% | 0.33% | -3.91% |
3-Month Return | -26.05% | -8.58% | -0.59% |
6-Month Return | -45.69% | -4.26% | 3.45% |
1-Year Return | 44.63% | 1.27% | 22.31% |
3-Year Return | -99.75% | 5.33% | 25% |
5-Year Return | -99.95% | 38.09% | 77.23% |
10-Year Return | -99.94% | 102.29% | 188.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 6.75M | 6.70M | 5.40M | 18.05M | 1.92M | [{"date":"2019-12-31","value":37.39,"profit":true},{"date":"2020-12-31","value":37.11,"profit":true},{"date":"2021-12-31","value":29.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":10.66,"profit":true}] |
Cost of Revenue | 11.63M | 300.00K | 1.49M | 3.43M | 1.28M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":2.58,"profit":true},{"date":"2021-12-31","value":12.82,"profit":true},{"date":"2022-12-31","value":29.53,"profit":true},{"date":"2023-12-31","value":11.04,"profit":true}] |
Gross Profit | (4.88M) | 6.40M | 3.91M | 14.62M | 640.00K | [{"date":"2019-12-31","value":-33.38,"profit":false},{"date":"2020-12-31","value":43.78,"profit":true},{"date":"2021-12-31","value":26.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":4.38,"profit":true}] |
Gross Margin | (72.29%) | 95.52% | 72.38% | 80.98% | 33.26% | [{"date":"2019-12-31","value":-75.68,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":75.77,"profit":true},{"date":"2022-12-31","value":84.77,"profit":true},{"date":"2023-12-31","value":34.82,"profit":true}] |
Operating Expenses | 24.71M | 53.69M | 86.04M | 52.06M | 640.00K | [{"date":"2019-12-31","value":28.72,"profit":true},{"date":"2020-12-31","value":62.4,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.5,"profit":true},{"date":"2023-12-31","value":0.74,"profit":true}] |
Operating Income | (17.39M) | (26.95M) | (82.13M) | (37.44M) | (23.44M) | [{"date":"2019-12-31","value":-1739400000,"profit":false},{"date":"2020-12-31","value":-2695300000,"profit":false},{"date":"2021-12-31","value":-8213400000,"profit":false},{"date":"2022-12-31","value":-3744000000,"profit":false},{"date":"2023-12-31","value":-2344400000,"profit":false}] |
Total Non-Operating Income/Expense | 1.52M | 5.71M | (4.80M) | (8.36M) | (12.53M) | [{"date":"2019-12-31","value":26.67,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-84.03,"profit":false},{"date":"2022-12-31","value":-146.28,"profit":false},{"date":"2023-12-31","value":-219.3,"profit":false}] |
Pre-Tax Income | (15.99M) | (67.18M) | (84.55M) | (41.63M) | (31.53M) | [{"date":"2019-12-31","value":-1599100000,"profit":false},{"date":"2020-12-31","value":-6717700000,"profit":false},{"date":"2021-12-31","value":-8454500000,"profit":false},{"date":"2022-12-31","value":-4163000000,"profit":false},{"date":"2023-12-31","value":-3153000000,"profit":false}] |
Income Taxes | 280.00K | (2.79M) | (196.00K) | 28.00K | 14.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-997.5,"profit":false},{"date":"2021-12-31","value":-70,"profit":false},{"date":"2022-12-31","value":10,"profit":true},{"date":"2023-12-31","value":5,"profit":true}] |
Income After Taxes | (16.27M) | (64.38M) | (84.35M) | (41.66M) | (31.54M) | [{"date":"2019-12-31","value":-1627100000,"profit":false},{"date":"2020-12-31","value":-6438400000,"profit":false},{"date":"2021-12-31","value":-8434900000,"profit":false},{"date":"2022-12-31","value":-4165800000,"profit":false},{"date":"2023-12-31","value":-3154400000,"profit":false}] |
Income From Continuous Operations | (16.27M) | (64.38M) | (84.35M) | (41.66M) | (33.19M) | [{"date":"2019-12-31","value":-1627075300,"profit":false},{"date":"2020-12-31","value":-6438310100,"profit":false},{"date":"2021-12-31","value":-8434900000,"profit":false},{"date":"2022-12-31","value":-4165800000,"profit":false},{"date":"2023-12-31","value":-3318800000,"profit":false}] |
Income From Discontinued Operations | 198.21K | 883.78K | (27.00K) | - | - | [{"date":"2019-12-31","value":22.43,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3.06,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.27M) | (64.38M) | (84.35M) | (41.66M) | (31.54M) | [{"date":"2019-12-31","value":-1627100000,"profit":false},{"date":"2020-12-31","value":-6438400000,"profit":false},{"date":"2021-12-31","value":-8434900000,"profit":false},{"date":"2022-12-31","value":-4165800000,"profit":false},{"date":"2023-12-31","value":-3154400000,"profit":false}] |
EPS (Diluted) | (3.36) | (10.56) | (9.96) | (4.48) | (117.76) | [{"date":"2019-12-31","value":-336,"profit":false},{"date":"2020-12-31","value":-1056,"profit":false},{"date":"2021-12-31","value":-996,"profit":false},{"date":"2022-12-31","value":-448,"profit":false},{"date":"2023-12-31","value":-11776,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AVTX | |
---|---|
Cash Ratio | 1.35 |
Current Ratio | 1.42 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AVTX | |
---|---|
ROA (LTM) | -30.64% |
ROE (LTM) | -42.52% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AVTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.79 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.21 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AVTX | |
---|---|
Trailing PE | 0.07 |
Forward PE | NM |
P/S (TTM) | 89.32 |
P/B | 3.48 |
Price/FCF | NM |
EV/R | 2.74 |
EV/Ebitda | NM |
Avalo Therapeutics Inc (AVTX) share price today is $6.87
Yes, Indians can buy shares of Avalo Therapeutics Inc (AVTX) on Vested. To buy Avalo Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Avalo Therapeutics Inc (AVTX) via the Vested app. You can start investing in Avalo Therapeutics Inc (AVTX) with a minimum investment of $1.
You can invest in shares of Avalo Therapeutics Inc (AVTX) via Vested in three simple steps:
The 52-week high price of Avalo Therapeutics Inc (AVTX) is $22.47. The 52-week low price of Avalo Therapeutics Inc (AVTX) is $3.95.
The price-to-earnings (P/E) ratio of Avalo Therapeutics Inc (AVTX) is 0.0741
The price-to-book (P/B) ratio of Avalo Therapeutics Inc (AVTX) is 3.48
The dividend yield of Avalo Therapeutics Inc (AVTX) is 0.00%
The market capitalization of Avalo Therapeutics Inc (AVTX) is $71.89M
The stock symbol (or ticker) of Avalo Therapeutics Inc is AVTX